DUPIXENT specifically targets the IL-4α receptor in severe asthma1–3

The interleukins; IL-4 and IL-13, are important in the development of Type 2 inflammation and its downstream effects in severe asthma2–7

DUPIXENT is a fully human monoclonal antibody for administration by subcutaneous injecton1

Learn more about how DUPIXENT works

DUPIXENT inhibits IL-4 and IL-13 signalling1,2


Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131–4

Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41–4

Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131–4

Inhibition of IL-4 and IL-13 markedly decreases:1,2

Total and
allergen-specific IgE

lung inflammation

Fractional exhaled nitric oxide (FeNO), a marker
of IL-13 related to lung inflammation


DUPIXENT can be administered via
a pre-filled pen or a syringe1

Dupixent packs

Mode of disease

Learn more about the triggers of severe asthma.

Find out more

Safety profile

Learn more about the safety profile of DUPIXENT.

Find out more

Complexity of Type 2 inflammation

Learn more about the biomarkers involved in Type 2 inflammation.

Find out more

    FeNO, fractional exhaled nitric oxide; IgE, Immunoglobulin E; IL, interleukin; R, receptor; γC, gamma C subunit.


    1. Sanofi Genzyme. Dupixent Summary of Product Characteristics, September 2021.
    2. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
    3. Krings JG, et al. J Allergy Clin Immunol Pract. 2019;7(5):1379–1392.
    4. Doran E, et al. Front Med. 2017;4:139.
    5. Tran TN, et al. Ann Allergy Asthma Immunol. 2016;116(1):37–42.
    6. Seys SF, et al. Respir Res. 2017;18:39.
    7. Peters MC, et al. J Allergy Clin Immunol. 2014;133(2):388–394.

MAT-GB-2004974(v4.0) | Date of preparation: February 2022